News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Top Five NSFW AI Chat and Image Tools You Must Try in January 2024

Summit Ventures BV

In today's tech-savvy world, we're increasingly connecting with AI chatbots for entertainment and interaction. With numerous options available, there are over 120 NSFW AI chat and image tools ready for your exploration. This article serves as your guide to the top NSFW AI chat and image tools that are a must-try, featuring AI hentai and AI writer capabilities! Table of Featured AI Chat and Image Tools 1. GPTGirlfriend.online 2. ChaiApp.pro 3. AI-Girlfriend.co 4. SexyFurries.com 5. AI-Companion.co Top Five Engaging and Diverse AI Chat and Image Tools The world of AI chatbots has seen significant growth, offering a variety of engaging options. While each chatbot brings its own unique features to the table, GPTGirlfriend.online stands out with its exceptionally engaging interactions and a wide range of capabilities. GirlfriendGPT: Chat with 25,000+ NSFW AI Characters GirlfriendGPT is an innovative AI-powered tool that brings your favorite anime characters to life, offering interactive experiences. This platform provides a wide array of activities, enabling you to create a virtual space for engaging conversations with your AI character companion. Moreover, GirlfriendGPT offers unrestricted content for a diverse experience, including an AI Hentai Image Generator and AI Writer. Key Features: Empowers you to create your personalized AI character companion. Allows unrestricted interactions and NSFW chats and conversations. Provides NSFW AI chatbot options, granting control over explicit content. Offers affordable premium and deluxe subscription plans. Resumes conversations with long-term memory. Chai App: Experience NSFW Chats with AI Characters Chai App stands out with its excellent website design and user-friendly interface, making it ideal for forging connections. This platform excels in creating companionship with a variety of AI characters. The AI NSFW chatbot seamlessly resembles a typical messenger app, enhancing realism. Additionally, Chai App allows you to customize your AI companion. Key Features: Intuitive navigation. Realistic chatbot interactions. Offers a diverse selection of AI companions. Allows customization of AI companions. Features AI Hentai Image Generator and AI Writer capabilities. AI Girlfriend: Personalized AI Girlfriends for Spicy Chat For those seeking personalized NSFW AI companions, AI Girlfriend is the perfect choice. Much like NSFW Character AI, this platform empowers you to tailor your own AI anime companion, adhering to your specific preferences. AI Girlfriend brings your ideal NSFW AI character to life, offering engaging and realistic interactions. Key Features: Provides realistic AI companion interactions with varied emotions and backgrounds. Abundance of features available for diverse AI character interactions. Offers budget-friendly pricing compared to other NSFW AI chatbots. Allows for the creation of a personalized AI companion. Sexy Furries: Explore Desires with Furry AI Chatbots Sexy Furries is renowned for having the best Furry characters in the AI chat and image tool world. This platform specializes in catering to intimate conversations and activities with AI chatbots. These AI companions provide natural and realistic responses, making it an ideal platform for those interested in NSFW and adult content. Key Features: Multilingual AI companion interactions. Customizable chatbot to align with personal preferences. Accommodates various interests and preferences in AI characters. Incorporates Image Generator capabilities. AI Companion: Engage with Customizable Chatbots AI Companions is a leading platform known for its wide range of character options in the AI chat and image tool domain. This versatile platform is designed to accommodate a variety of conversations and interactions with AI chatbots. Whether users are looking for engaging, realistic responses for everyday topics or exploring more mature themes, AI Companions offers a tailored experience for every user. Key Features: Support for multiple languages, enhancing global accessibility. Personalization options to tailor the chatbot according to individual preferences. Broad spectrum of interests and character types to suit diverse user needs. Advanced Image Generator technology for a more immersive experience. Frequently Asked Questions Q: Is there any age restriction for using NSFW AI chat and image tools? A: Yes, you have to be at least 18 years old and above as these tools contain restricted content suitable for adults. Q: Which AI tools allow NSFW content? A: Many AI companion chat and image tools offer NSFW content, with gptgirlfriend.online among the top platforms. Q: Do Character.AI tools allow explicit content? A: Some AI platforms allow explicit content, while others do not. Q: What is the AI tool suitable for flirtatious interactions? A: GirlfriendGPT is perfect for flirtatious interactions with AI characters, offering unique and realistic conversations with a variety of AI Anime characters. Q: Which AI chat and image tools do not filter NSFW content? A: GirlfriendGPT provides a great NSFW experience without content filtering. Q: What is the most cost-effective NSFW AI chat and image tool? A: GirlfriendGPT is among the most cost-effective AI chat and image tools, with plans starting with a free trial, offering an enjoyable experience with your NSFW AI companion. Q: Are NSFW AI chat and image tools safe to use? A: Yes! Platforms like GirlfriendGPT provide a secure and unrestricted environment for engaging with AI companions. They prioritize delivering a realistic and enjoyable experience while ensuring safety. In Conclusion As technology continues to advance, NSFW AI chat and image tools offer unique opportunities for users to establish virtual connections and relationships with their AI companions. These tools enable the expression and experience of emotions such as affection, comfort, and shared feelings in a virtual space. They bridge the gap between the virtual and real worlds, providing an innovative way to connect with AI characters. We encourage you to explore these NSFW AI chat and image tools, each offering a distinctive experience and limitless possibilities. GPTGirlfriend.online is the most advanced AI companion subscription service with a community of more than 500,000 Monthly Active Users. With more than 25,000 characters, it has transformed how people interact with and experience AI. Please refer to our detailed Terms of Use and Community Guidelines for comprehensive information on usage, safety, and ethical considerations on GPTGirlfriend.online Contact Details GPTGirlfriend Business Enias hello@enias.io Company Website https://www.gptgirlfriend.online

January 16, 2024 11:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Taking the Guesswork Out of Finding the Right Therapist with Two Chairs

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/_XF1w-pVxZs While more Americans are seeking therapy than ever before, many people are matched with the wrong therapist. Two Chairs, the leader in connecting patients to the right therapist, has developed a solution called Matchmaker, an industry-leading technology platform that expertly connects people with the right therapist based on their health history, personal background, and clinical needs. Research shows that a strong client-therapist relationship is the key to great therapy but finding the right therapist can feel overwhelming. Knowing where to start and what makes a great patient-therapist match saves time and increases the likelihood of success. Data shows that the majority of people attend just one therapy session before quitting: ● 1 in 5 patients quit therapy prematurely because they don’t trust their therapist. ● Data finds that a strong patient-therapist relationship is the single best predictor of therapy success. ● Recent research shows that an average 15-20 sessions are needed for 50% of patients to recover. When Two Chairs hires a new therapist, Matchmaker analyzes their strengths, experiences, and skill sets, zeroing in on clinical presentations, diagnoses, focus areas, and demographics. For example, a therapist highly skilled in treating panic disorders may be less adept at addressing postpartum depression. Conversely, a clinician who has limited experience in Acceptance and Commitment Therapy may demonstrate a high level of expertise in utilizing Dialectical Behavior Therapy. This meticulous process ensures that the precise therapist-patient pairing is fine-tuned to match an individual's needs. Two Chair’s Matchmaker process considers over 300 factors, including therapy types (such as dynamic, emotion-focused, cognitive-behavioral, etc.), clinical styles, specific disorder expertise (anxiety, mood, trauma, addiction, eating, personality, etc.), life stages, relationships, identity, and more. Additionally, therapists can stipulate therapeutic approaches they choose not to practice, serving as a safeguard for both patients and clinicians. This comprehensive analysis ensures a tailored and optimal match for individuals seeking therapy. Established with the goal of providing the highest quality outpatient mental health care system in the United States, Two Chairs boasts an impressive patient retention rate, with 90% of their patients continuing to a fourth session—significantly surpassing the national average of 33%. Key to their treatment success is one of the most rigorous and sophisticated clinician-patient matching processes on the market. Two Chairs’ newly launched Matchmaker features further empower clinicians to practice at the top of their license, allowing them to focus on cases they are most skilled in treating. On January 10th, a media tour was conducted featuring Colleen Marshall, Vice President of Clinical Care at Two Chairs and a Licensed Marriage and Family therapist, to discuss the new Matchmaker feature and the importance of measuring outcomes to ensure clients get better faster. With a growing team of 500 licensed clinicians across 90 areas of expertise, Two Chairs has more than 20 million covered lives. Topics that Colleen Marshall discussed during the media tour included: ● Why a strong client-therapist relationship is crucial for effective therapy. ● Why it’s important to prioritize your mental health and destigmatize getting help. ● Reasons why people quit therapy, emphasizing the importance of a good therapist match for a long-term relationship that will lead to better outcomes. ● Why Two Chairs' developed the Matchmaker feature, delving into how it works to improve therapist-patient connections. For more information, visit TwoChairs.com About Two Chairs Two Chairs was founded in 2017 with a mission to build a world where everyone has access to exceptional mental healthcare. We're creating a better experience for both patients and clinicians by starting with an in-depth, research-backed matching process to ensure the ideal patient-therapist fit, offering hybrid care that gives patients and clinicians flexibility between in-person and virtual sessions, and measuring outcomes to ensure patients get better faster. With a growing team of 50 licensed clinicians across 90 areas of expertise, Two Chairs has more than 20 million covered lives Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 16, 2024 10:00 AM Eastern Standard Time

Video
Article thumbnail News Release

New Year, Healthiest You: Real Talk About Weight Loss Medication

YourUpdateTV

It’s that time of year again - New Year, Healthiest You! When we think about health goals which often include weight management, there is no avoiding the white hot topic of weight loss medications. Recently, Hims and Hers medical experts, Dr. Craig Primack, Leading Obesity Medicine Expert and SVP Weight Management and Dr. Jessica Yu, Clinical Psychologist and Sr. Director of Patient Experience, participated in a nationwide satellite media tour to discuss weight loss medication, how to achieve sustained success, and the connections between emotions, weight management and mental health. A video accompanying this announcement is available at: https://youtu.be/3EJ0WhNYiEE With stats showing 7 in 10 American adults are overweight or obese, it’s no surprise the conversation around weight loss medication took off like wildfire and it’s not stopping anytime soon. Leading health & wellness platform, Hims & Hers, recently launched Weight Loss by Hims & Hers, a comprehensive and customizable prescription based alternative to the GLP-1’s (i.e. Ozempic, Wegovy, Mounjaro) that have dominated headlines recently. Addressing the major roadblock of cost, accessibility and lasting results - this personalized weight management program is affordable (no insurance needed), offers oral based medication, and provides customers with ongoing content and coaching throughout their health and fitness journey. Weight loss is both a physical and psychological endeavor. By addressing underlying factors that contribute to weight gain including nutrition, behavior, and movement - Hims & Hers creates a tailored holistic plan in order for customers to lose and keep off the weight leading to long-term health benefits. For more information, visit hims.com or forhers.com About Dr. Craig Primack Dr. Craig Primack MD, FACP, FAAP, FOMA is a physician specializing in obesity medicine. He is the co-founder of Scottsdale Weight Loss Center in Scottsdale, Arizona, where he began practicing full-time obesity medicine. Primack completed a combined residency in Internal Medicine and in Pediatrics at Banner University- Phoenix, and Phoenix Children's Hospital. Dr. Primack received post-residency training in Obesity Medicine and is one of about 7,000 physicians in the US certified by the American Board of Obesity Medicine. He completed his undergraduate studies at the University of Illinois and subsequently attended medical school at Loyola University - The Stritch School of Medicine. Dr Primack routinely does media interviews regarding weight loss and regularly speaks around the country educating medical professionals about weight loss and obesity care. He is co-author of the book, “Chasing Diets”. About Dr. Jessica Yu Dr. Jessica Yu is the Senior Director of Patient Experience at Hims & Hers. She is a clinical psychologist whose professional mandate has been to bring evidence-based mental healthcare to those in need in new and interesting ways. At Hims & Hers, she works to uphold psychological principles at every step of the mental health journey, develop new ways of helping people achieve their emotional and mental health goals and contribute to thought leadership. Dr. Yu holds a Bachelor of Arts degree in Human Biology from Stanford University and a Ph.D. in Clinical Psychology from Rutgers, the State University of New Jersey. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 12, 2024 02:18 PM Eastern Standard Time

Video
Article thumbnail News Release

UDS Service Dogs Program Achieves Accreditation by Assistance Dogs International

UDS

United Disabilities Services (UDS) Service Dog Program, an assistance dog program dedicated to assisting people with disabilities, is pleased to announce that it achieved reaccreditation by Assistance Dogs International (ADI). ADI is the leading authority in the Assistance Dogs industry. It establishes and promotes standards of excellence in all areas of assistance dog acquisition, training and partnership. UDS Service Dogs trains puppies starting at the age of 8 weeks to work as Service Dogs for people with mobility challenges and autism, Facility Dogs in school districts and therapy offices as well as Veterans with PTSD. We mainly work with Labrador Retrievers due to their high work drive, however recently there has been a high demand for non-shedding breeds and we are now working with Labradoodles, Goldendoodles, Bernedoodles and Aussiedoodles to address those client needs. Once accredited, a program becomes a member of ADI. Member programs must complete a reaccreditation every 5 years to comply with ADI’s Standards of Practice. ADI accreditation is a peer-review process conducted by a trained ADI assessor over a period of two to four days. Currently there are 155 ADI-accredited assistance dog programs in the world. About UDS Foundation UDS Foundation is a Lancaster, PA-based organization whose mission is to improve the lives of people with physical and age-related disabilities. UDS accomplishes that by providing a variety of home- and community-based services to help people with disabilities enjoy safer, happier, and more independent lives in the comfort of their homes. Incorporated in 1970, UDS has evolved from a small organization to a company providing a network of 12 different programs through several nonprofit and for-profit entities. UDS serves individuals with disabilities, including the aging and veterans, throughout Pennsylvania and coordinates a network of business partners and satellite offices in multiple counties. For more information, visit www.udservices.org. About Assistance Dogs International Assistance Dogs International (ADI) is a worldwide coalition of non-profit organizations that raise, train and place assistance dogs. The mission of ADI is to foster a collaborative global community dedicated to the highest standards of excellence for the assistance dog industry. For more information, visit www.assistancedogsinternational.org or contact Chris Diefenthaler, ADI’s Executive Director at chris@assistancedogsinternational.org or +1- 419-350-5788 Contact Details United Disabilities Services Service Dogs Lori Breece +1 717-715-8753 lorib@udservices.org Company Website https://udservices.org

January 11, 2024 04:56 PM Eastern Standard Time

Image
Article thumbnail News Release

Innovations and policy updates drive equity and a record number of lifesaving organ transplants in 2023

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) announced another record year for organ transplants, with 46,632 transplants performed in 2023 thanks to the selfless and generous gifts from donors. In addition, 10,824 Black patients received transplants last year, more than any year prior. UNOS, the engine that powers the national organ donation and transplantation system under contract with and oversight from the federal government, manages the national transplant waitlist that matches patients with lifesaving organs. UNOS tracks the number of transplants performed for each organ and identifies trends in organ donation and transplantation. Last year marked the 13 th consecutive year of a record number of deceased donors. Additional milestones reached include: More than 16,000 individuals became deceased donors, making 39,679 deceased donor transplants possible. That's nearly a 9% increase from 2022. There were 10,660 liver transplants performed in 2023 – the most ever performed in a single year. A 30% increase from 2022 in donors aged 65 years and older, representing a greater acceptance by the transplant community and candidates to receive organs from medically more complex donors. “It is important to remember that these milestones are more than just numbers – they reflect real people who can go on hikes with their spouse again and got to spend the holidays with their loved ones,” said Maureen McBride, Ph.D., CEO of UNOS. “I also want to recognize the selfless donors whose generosity made these life-changing transplants possible. I am grateful and thankful for each donor and know that as long as we remember the profound ripple effect of their decision, we will never lose sight of our mission.” The increase in transplants in 2023 is the result of several initiatives that have helped increase equity and enhance patient access to transplants, which were driven by the organ donation and transplant community and the Health Resources and Services Administration, the federal government agency overseeing the Organ Procurement and Transplantation Network (OPTN). Some of these policy updates and technological advancements include removing race from kidney function measurements, increasing equity in lung transplants through continuous distribution, and making it easier for transplant programs to filter organ offers so an available organ is transplanted more quickly. The transplant community’s commitment to continuous system improvements drives the year-over-year increases in the number of lifesaving and lifechanging transplants performed. These improvements are necessary to ensure that each of the more than 103,000 patients on the national waitlist has an opportunity to receive a transplant. UNOS continues to work with the organ donation and transplant community and the federal government to advance its Action Agenda, a series of reforms to improve the organ donation and transplant system. This includes advocating for access to pre-waitlist data to enhance equity and to make it easier for organs to be transported in the cabin of commercial airplanes to help reduce the time it takes for an organ to get to a patient. Additionally, the OPTN is spearheading the Expeditious Task Force that is taking massive steps forward to reduce organ non-use. “Patients and donors motivate us to work collaboratively with the organ donation and transplant community and the government to strengthen the system,” continued McBride. “That way even more patients can access and receive high-quality and equitable transplant care.” For more information on 2023’s organ donation and transplant numbers and to learn more about the patients and donors, please visit: unos.org. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

January 11, 2024 08:51 AM Eastern Standard Time

Image
Article thumbnail News Release

Defense Acquisition University (DAU) to Support NCMA Nexus 2024

National Contract Management Association

The National Contract Management Association (NCMA) is pleased to announce the collaboration with the Defense Acquisition University (DAU) for the inaugural Nexus 2024 conference, scheduled from March 3-6 in Jacksonville, FL. This strategic partnership is a significant milestone for NCMA as it reinforces the commitment to advancing the knowledge and skills of the defense acquisition workforce. Notably, participants in Nexus 2024 will benefit from transferable credits toward their certifications, making this collaboration with DAU particularly valuable for professionals seeking career development opportunities. Nexus 2024, offers a unique platform for cross-functional collaboration for both government and industry to address pressing issues in federal procurement, including supply chain risk, cybersecurity, and sustainability. The event encourages joint efforts in innovation, strategic discussions, case studies, hackathons, and real-world problem-solving, providing deployable solutions for attendees. The co-hosted event aligns seamlessly with the new Better Contracting Initiative (BCI), emphasizing that multi-functional groups come together to learn the acquisition lifecycle side by side, promoting a comprehensive understanding of each’s others perspective job functions along with federal procurement challenges. One of the emcees for Nexus 2024 is DAU’s Professor of Program Management, Julie Knechtel, expressed her excitement about the event, stating, "I am excited to be part of an event that brings together diverse perspectives and expertise in defense acquisition. It is a great opportunity to train as we work, leverage the expertise of multi-functional teams, and enhance the skills needed to tackle the evolving challenges in federal procurement collaboratively." NCMA's Chief Executive Officer, Kraig Conrad, commented on the natural fit between NCMA and DAU, saying, "The collaboration with DAU at Nexus 2024 exemplifies our shared commitment to advancing the knowledge and skills of the acquisition workforce. We are grateful for their support as together we drive better practices and better outcomes in acquisition and procurement.” Michelle Currier, NCMA's Chief Learning Officer, also shared her enthusiasm, stating, "The Nexus 2024 event underscores the importance of collaboration and continuous learning in federal procurement. DAU's support enhances the educational value of the event, aligning with the goals of not only NCMA, but the federal government overall." Nexus 2024 is open to all professionals involved in federal procurement, providing an ideal opportunity for integrated teams to learn and train together. For more information about Nexus 2024 and to register for the event, visit the NCMA website at http://www.ncmahq.org/nexus. The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. DAU is the acquisition learning, development and talent management organization for the Department of Defense with a mission to provide a global learning environment to develop qualified acquisition, requirements, and contingency professionals who deliver and sustain effective and affordable warfighting capabilities. Nearly 160,000 acquisition professionals across all military services and Department of Defense agencies have access to career-long learning and support from DAU faculty and staff. Contact Details Holly DeHesa +1 281-865-3296 dominick.belfiore@ncmahq.org Company Website https://www.ncmahq.org

January 11, 2024 05:05 AM Eastern Standard Time

Article thumbnail News Release

UNOS Hires New Vice President of External Affairs

United Network for Organ Sharing

The United Network for Organ Sharing (UNOS) has hired Alicia Hennie as its new vice president for external affairs. As the leader of the external affairs team, Hennie advocates for impactful policies and legislation on behalf of transplant patients with the mission of saving as many lives as possible. She’s responsible for strengthening and growing relationships with federal and state government and regulatory officials, as well as patient groups and industry groups. Hennie joins UNOS with more than two decades of public policy and advocacy experience. She previously served as a presidential appointee at the U.S. Department of Health and Human Services and has worked for the Senate Aging Committee and the Senate HELP Committee. More recently, she held senior government affairs roles at PhRMA and Varian, a Siemens Healthineers Company. “Alicia has been advocating for patients for nearly 20 years and will be a great champion for our nation’s transplant patients and organ donors,” said UNOS Chief of Staff Julie Nolan, who previously held the vice president of external affairs role. “I’m confident her experience and relationships will drive meaningful changes that will strengthen the organ donation and transplant system, helping more patients get the lifesaving transplants they need.” Hennie is based in Washington, D.C. She has a bachelor’s degree in history from Wheaton College. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

January 10, 2024 04:14 PM Eastern Standard Time

Image
Article thumbnail News Release

G Medical Innovations Announces First Half 2023 Financial Results and Provides Business Update

G Medical Innovations Holdings Ltd

G Medical Innovations Holdings Ltd. (Nasdaq: GMVDF) (“G Medical” or the “Company”), an early commercial stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2023. First Half 2023 Financial Results The Company reported total revenues for the six-month period ended June 30, 2023 in the amount of approximately $3.1 million, compared with approximately $1.9 million for the six months ended June 30, 2022 Cash and cash equivalents as of June 30, 2023, were $2,009 thousand, compared to $295 thousand as of December 31, 2022. The increase compared to December 31, 2022, mainly reflects less cash used in operating activities and lower investments in fixed assets during the six months ended June 30, 2022. Research and development expenses for the six months ended June 30, 2023, were $972 thousand, representing a decrease of $217 thousand compared to $1,189 thousand in the six months ended June 30, 2022. The decrease is related to the products segment and is mainly related to the decrease of salaries and related expenses as well as in subcontractors. Selling, general, and administrative expenses for the six months ended June 30, 2023, were $8,202 thousand, representing a decrease of $3,889 thousand compared to $12,091 thousand in the six months ended June 30, 2022. The decrease is related mainly to a decrease in share-based compensation expenses in the amount of $1,327 thousand and to a decrease in share issuance costs of 1,545 thousand. Net loss for the six months ended June 30, 2023, was $6,083 thousand, or $1.13 per share attributed to shareholders of the Company, compared to $ 13,287 thousand or after giving effect to the reverse stock split in 2022, $ 25.31 per share attributed to shareholders of the Company, in the six months ended June 30, 2022. The decrease in net loss was mainly attributed to the Company's COVID-19 business activities. Net cash used in operating activities during the six months ended June 30, 2023, was $7,254 thousand, compared to $16,424 thousand during the six months ended June 30, 2022. The decrease consists primarily of net loss and revaluation of liability in respect of derivative liabilities. “The Company expects growth in its patient monitoring business”, said Dr. Yacov Geva, Chief Executive Officer of G Medical. The complete report is available on the company’s website, https://gmedinnovations.com/investors About G Medical Innovations Holdings Ltd. G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch; and 31 different at-home health tests kits. In addition, the Company is developing its Wireless Vital Signs Monitoring System, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its future financial performance. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to maintain access to sources of liquidity; the Company’s ability to successfully market its products and services; the Company’s expectation regarding government and third-party payors providing adequate coverage and reimbursement for the use of its products and services, including the Company’s COVID-19 and other related testing services; the acceptance of its products and services by customers; the Company’s continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other medical device and at-home test kit businesses; the Company’s ability to successfully develop new products and services; the Company’s success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the Company’s ability to comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2023, and in any subsequent filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Investor Relations Contact G Medical Innovations Holdings Ltd. +972 8-958-4777 service@gmedinnovations.com Dr. Yacov Geva G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch; and 31 different at-home health tests kits. In addition, the Company is developing its Wireless Vital Signs Monitoring System, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility monitoring services and private monitoring services. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its future financial performance. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to maintain access to sources of liquidity; the Company’s ability to successfully market its products and services; the Company’s expectation regarding government and third-party payors providing adequate coverage and reimbursement for the use of its products and services, including the Company’s COVID-19 and other related testing services; the acceptance of its products and services by customers; the Company’s continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other medical device and at-home test kit businesses; the Company’s ability to successfully develop new products and services; the Company’s success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the Company’s ability to comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2023, and in any subsequent filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details Rina Bar +972 54-724-0412 rinab@gmedinnovations.com Company Website https://gmedinnovations.com

January 10, 2024 03:01 PM Eastern Standard Time

Article thumbnail News Release

Human-augmented AI data marketplace Ta-Da debuts on strategic MultiversX incubator xLaunchpad

STORM Partners

Ta-Da, the platform revolutionizing AI data annotation, announces its highly anticipated debut on xLaunchpad, MultiversX’s strategic incubator. This collaboration sets the stage for a groundbreaking advancement in the secure and ethical development of AI, harnessing the power of human-validated data. Founded on over seven years of expertise in AI, Ta-Da leverages the power of MultiversX blockchain technology to disrupt conventional data collection methods. With its focus on video, audio, and image verticals, Ta-Da introduces a hybrid model of data annotation that blends quality, cost-effectiveness, and scalability. Addressing major challenges in AI development, such as bias and high data-related costs, this approach has already proven its efficacy with over 2.5 million tasks completed during its public beta phase. “The future of AI is not just about algorithms but about the quality and diversity of data that trains these algorithms,” says William Simonin, CEO of Ta-Da. “ Our launch on xLaunchpad is a pivotal step in realizing our vision of creating more effective AI systems by harnessing the power of human insight and the robustness of blockchain technology. ” xLaunchpad is the strategic incubator and acceleration platform of the MultiversX blockchain ecosystem. It is renowned for backing the most ambitious and impactful technologies in the web3 space, enabling them to leverage MultiversX’s highly scalable and secure blockchain network, which processes over 30,000 transactions per second at negligible cost. “ Ta-Da’s innovative model for AI data annotation aligns perfectly with our mission to foster technological advancements that have a profound global impact, ” said Beniamin Mincu, CEO and founder of MultiversX. “ Their debut on xLaunchpad is a testament to our commitment to nurturing projects that tap into the massive opportunities that emerge from the convergence of blockchain and AI. ” The collaboration between Ta-Da and xLaunchpad signifies a transformative movement in AI and blockchain technology. It not only propels Ta-Da’s mission forward but also reinforces MultiversX’s position as a leader in supporting revolutionary tech initiatives. This partnership is set to redefine the landscape of AI development, making it more accessible, diverse, and efficient. The public launch event of Ta-Da on xLaunchpad is taking place on February 09, 2024. For more information and to be part of this transformative journey, visit https://xlaunchpad.com/tada About MultiversX MultiversX is a highly scalable, secure, and decentralized blockchain network built from first principles, to solve the two fundamental problems critical for widespread, global adoption: a transition from dialup to broadband, and a significant UX paradigm shift. Distributed by STORM Partners. Contact Adrian Bono for interviews and quotes -adrian.bono@storm.partners or telegram @STORMPartners Contact Details Dan Voicu +1 561-325-8757 dan.voicu@multiversx.com

January 10, 2024 09:12 AM Eastern Standard Time

Image
1 ... 3031323334 ... 272